227 related articles for article (PubMed ID: 37458162)
21. At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.
Moreno L; Marshall LV; Pearson AD
Br Med Bull; 2013; 108():173-88. PubMed ID: 24211816
[TBL] [Abstract][Full Text] [Related]
22. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
23. Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.
Gamis AS; Alonzo TA; Perentesis JP; Meshinchi S;
Pediatr Blood Cancer; 2013 Jun; 60(6):964-71. PubMed ID: 23255301
[TBL] [Abstract][Full Text] [Related]
24. Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.
Grupp SA; Dvorak CC; Nieder ML; Levine JE; Wall DA; Langholz B; Pulsipher MA;
Pediatr Blood Cancer; 2013 Jun; 60(6):1044-7. PubMed ID: 23255402
[TBL] [Abstract][Full Text] [Related]
25. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.
Liang WH; Federico SM; London WB; Naranjo A; Irwin MS; Volchenboum SL; Cohn SL
JCO Clin Cancer Inform; 2020 Oct; 4():895-905. PubMed ID: 33058692
[TBL] [Abstract][Full Text] [Related]
26. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research.
Øra I; Eggert A
Semin Cancer Biol; 2011 Oct; 21(4):217-28. PubMed ID: 21798350
[TBL] [Abstract][Full Text] [Related]
27. Advances in Risk Classification and Treatment Strategies for Neuroblastoma.
Pinto NR; Applebaum MA; Volchenboum SL; Matthay KK; London WB; Ambros PF; Nakagawara A; Berthold F; Schleiermacher G; Park JR; Valteau-Couanet D; Pearson AD; Cohn SL
J Clin Oncol; 2015 Sep; 33(27):3008-17. PubMed ID: 26304901
[TBL] [Abstract][Full Text] [Related]
28. Children's Oncology Group's 2023 blueprint for research: Pharmacy.
Ostrenga AR; Thackray J; McLearan HH; Mulieri KM; Bisaccia E; Militano O; Dupuis LL; Bernhardt MB;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30581. PubMed ID: 37460409
[TBL] [Abstract][Full Text] [Related]
29. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
Pinto N; Naranjo A; Hibbitts E; Kreissman SG; Granger MM; Irwin MS; Bagatell R; London WB; Greengard EG; Park JR; DuBois SG
Eur J Cancer; 2019 May; 112():66-79. PubMed ID: 30947024
[TBL] [Abstract][Full Text] [Related]
30. Advances in neuroblastoma therapy.
MacFarland S; Bagatell R
Curr Opin Pediatr; 2019 Feb; 31(1):14-20. PubMed ID: 30480556
[TBL] [Abstract][Full Text] [Related]
31. Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics.
Fox E; Parsons DW; Weigel BJ;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30563. PubMed ID: 37430453
[TBL] [Abstract][Full Text] [Related]
32. [Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives].
Valteau-Couanet D; Minard-Colin V; Pasqualini C
Med Sci (Paris); 2019 Dec; 35(12):997-1000. PubMed ID: 31903906
[TBL] [Abstract][Full Text] [Related]
33. Neuroblastoma: biology, prognosis, and treatment.
Park JR; Eggert A; Caron H
Pediatr Clin North Am; 2008 Feb; 55(1):97-120, x. PubMed ID: 18242317
[TBL] [Abstract][Full Text] [Related]
34. Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.
Gustafson WC; Matthay KK
Expert Rev Neurother; 2011 Oct; 11(10):1411-23. PubMed ID: 21955198
[TBL] [Abstract][Full Text] [Related]
35. Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation.
Kitko CL; Bollard CM; Cairo MS; Chewning J; Fry TJ; Pulsipher MA; Shenoy S; Wall DA; Levine JE
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30577. PubMed ID: 37480158
[TBL] [Abstract][Full Text] [Related]
36. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.
Zage PE; Louis CU; Cohn SL
Pediatr Blood Cancer; 2012 Jul; 58(7):1099-105. PubMed ID: 22378620
[TBL] [Abstract][Full Text] [Related]
37. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
[TBL] [Abstract][Full Text] [Related]
38. A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN∗, COG∗∗, and GPOH∗∗∗.
Matthyssens LE; Nuchtern JG; Van De Ven CP; Gabra HOS; Bjornland K; Irtan S; Stenman J; Pio L; Cross KM; Avanzini S; Inserra A; Chacon JG; Dall'igna P; Von Schweinitz D; Holmes K; Fuchs J; Squire R; Valteau-Couanet D; Park JR; Eggert A; Losty PD; La Quaglia MP; Sarnacki S;
Ann Surg; 2022 Mar; 275(3):e575-e585. PubMed ID: 32649454
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
[TBL] [Abstract][Full Text] [Related]
40. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
Sokol E; Desai AV; Applebaum MA; Valteau-Couanet D; Park JR; Pearson ADJ; Schleiermacher G; Irwin MS; Hogarty M; Naranjo A; Volchenboum S; Cohn SL; London WB
J Clin Oncol; 2020 Jun; 38(17):1906-1918. PubMed ID: 32315273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
